Coverage Launched on Biotech That Could 'Disrupt the Skin Regeneration Market'

(MENAFN- Investors Ideas)

February 23, 2018 (Investorideas.com Newswire) Elemer Piros, a Cantor Fitzgerald analyst, explained this company's lead product, including how it works, its success to date and its market potential.

A Feb. 14 research note revealed Cantor Fitzgerald initiated coverage on , with an Overweight rating and a $70 per share price target, which reflects more than a triple, or 359% upside, from where the stock is currently trading at around $17.19. "We believe PolarityTE has demonstrated strong potential to disrupt the skin regeneration market," wrote analyst Elemer Piros.

PolarityTE has developed an autologous cell wound-healing product, SkinTE, which uses a small amount of a patient's own healthy skin to cover a wound up to 500 to 1,000 times its size, and results in skin regeneration in the affected area without the typical degree of scarring and/or contracture that can accompany natural healing.

With the use of SkinTE, the company has demonstrated "previously unseen results" of "flawless healing" in animals and positive early evidence in humans, Piros indicated. One of the first users of the product on a human was a physician who excised a "badly scarred, sizable (200 square centimeter) wound from the chest of a 10-year-old burn victim" and treated it with SkinTE. A month later, about midway through the healing process, the medical provider "proclaimed that the treatment 'definitely works.'"

Piros purported that "regeneration of fully functional skin while limiting these negative effects of natural wound healing has broad application in a market that is already commercially developed, but underserved."

With the commercial launch of SkinTE underway, PolarityTE continues building a 200,000-square-feet campus that can process about 230,000 products annually. At this scale with a single daily shift, at $7,300 apiece, revenue can reach $1.7 billion, Piros forecasted.

Cantor estimated the overall market potential of SkinTE at more than $600 million, "when reaching conservative peak market penetration of 85,000 wounds in 2023," added Piros. That figure increases as PolarityTE commercializes its additional products for bone, cartilage, heart and muscle, currently in development. Based on the results to date, PolarityTE has "already generated tremendous physician interest for use of the product in a variety of settings," Piros reported. Commercialization of the bone product OsteoTE is expected by year-end.

The next catalyst for PolarityTE, according to Cantor, is the release of SkinTE treatment case study data, anticipated in mid-2018.

Disclosure:

1) Doresa Banning compiled this article for Streetwise Reports LLC and provide services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.

2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click for important disclosures about sponsor fees.

3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal . This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of PolarityTE, a company mentioned in this article.

Disclosures from Cantor Fitzgerald, PolarityTE, Initiation of Coverage, Feb. 14, 2018

Analyst Certification

The analyst primarily responsible for this research report, and whose name appears on the front cover, certifies that: (i) all of the views expressed in this research report accurately reflects his or her personal views about any and all of the subject securities or issuers featured in this report; and (ii) no part of any of the research analyst's compensation was, is, or will be, directly or indirectly related to the specific recommendations or views expressed by the research analyst in this report.

Legal Disclosures

Investment banking (next 3 months): Cantor Fitzgerald and/or its affiliates, expect to receive, or intend to seek, compensation for investment banking services within the next three months from all of the companies referenced within this report.

Cantor Fitzgerald and/or its affiliates is a market maker in PolarityTE Inc.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: Learn more about publishing your news release on the Investorideas.com newswire

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: . Global investors must adhere to regulations of each country.

MENAFN2502201801420000ID1096514193

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.